

REMARKS

Status of Claims

Claims 1-19, 21-29, and 38-50 are pending and subject to a restriction requirement.

Claims 6-10, 12-14, 18, 21-23, 38, 45-48, and 50 are amended herein.

Claims 1-5, 15-17, 39-44, and 49 are cancelled herein without prejudice.

All claims find support in the specification as originally filed.

No new matter is introduced.

Applicant reserves the right to reintroduce cancelled subject matter, for example, in a later-filed continuing application.

Restriction Requirement

Applicant's Election of Invention and Species

According to the Office, "Group 1, claims 1-14, 18-19 and 21, [are] drawn to compound." Office Action at page 2, line 8. Of these claims, claims 6-14, 18-19, and 21 remain pending. Moreover, Applicant points out that claims 6-14 are drawn to a compound; claims 18-19 are drawn to a vaccine comprising the compound; and claim 21 is drawn to a pharmaceutical composition comprising the compound.

Applicant elects, with traverse, Group 1. Further, Applicant elects the species HIV gp120. It is believed that all claims read on the elected species.

The Restriction Requirement is Traversed

Applicant respectfully disagrees with the Examiner assertion regarding the requirement for restriction.

By the present amendment, Group 5 shares the same technical feature as Group 1 (PCT Rule 13.2), therefore, at least for this reason, Groups 1 and 5 should be considered to be the same invention under PCT Rule 13.1. Moreover, Group 8 shares the same compound as Group 1, therefore, at least for this reason, Groups 1 and 8 also should be considered to be in the same group.


CONCLUSIONS

The claims are now in condition for examination and allowance.

If the Office has any questions regarding this submission, the Examiner is invited to contact Applicants' undersigned representative using the information provided below.

Date: February 23, 2009

Respectfully submitted,


Alireza Behrooz
Registration No. 60,882

WOMBLE CARLYLE SANDRIDGE & RICE
P. O. Box 7037
Atlanta, Georgia 30357-0037
(404) 888-7363 (direct dial)
(336) 870-4832 (facsimile)